TY - JOUR T1 - A2B-COVID: A method for evaluating potential SARS-CoV-2 transmission events JF - medRxiv DO - 10.1101/2020.10.26.20219642 SP - 2020.10.26.20219642 AU - Christopher J. R. Illingworth AU - William L. Hamilton AU - Chris Jackson AU - Ashley Popay AU - Luke Meredith AU - Charlotte J. Houldcroft AU - Myra Hosmillo AU - Aminu Jahun AU - Matthew Routledge AU - Ben Warne AU - Laura Caller AU - Sarah Caddy AU - Anna Yakovleva AU - Grant Hall AU - Fahad A. Khokhar AU - Theresa Feltwell AU - Malte L. Pinckert AU - Iliana Georgana AU - Yasmin Chaudhry AU - Martin Curran AU - Surendra Parmar AU - Dominic Sparkes AU - Lucy Rivett AU - Nick K. Jones AU - Sushmita Sridhar AU - Sally Forrest AU - Tom Dymond AU - Kayleigh Grainger AU - Chris Workman AU - Effrossyni Gkrania-Klotsas AU - Nicholas M. Brown AU - Michael P. Weekes AU - Stephen Baker AU - Sharon J. Peacock AU - Theodore Gouliouris AU - Ian Goodfellow AU - Daniela de Angelis AU - M. Estée Török Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/27/2020.10.26.20219642.abstract N2 - Identifying linked cases of infection is a key part of the public health response to viral infectious disease. Viral genome sequence data is of great value in this task, but requires careful analysis, and may need to be complemented by additional types of data. The Covid-19 pandemic has highlighted the urgent need for analytical methods which bring together sources of data to inform epidemiological investigations. We here describe A2B-COVID, an approach for the rapid identification of linked cases of coronavirus infection. Our method combines knowledge about infection dynamics, data describing the movements of individuals, and novel approaches to genome sequence data to assess whether or not cases of infection are consistent or inconsistent with linkage via transmission. We apply our method to analyse and compare data collected from two wards at Cambridge University Hospitals, showing qualitatively different patterns of linkage between cases on designated Covid-19 and non-Covid-19 wards. Our method is suitable for the rapid analysis of data from clinical or other potential outbreak settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by COG-UK, which is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute; We also acknowledge the support from the Wellcome (Senior Clinical Fellowship to MPW (ref: 108070/Z/15/Z), Senior Research Fellowship to SB (ref: 215515/Z/19/Z), Senior Fellowship to IG (ref: 097997/Z/11/Z); Collaborative Grant to CJH (ref: 204870/Z/16/Z); the Academy of Medical Sciences & the Health Foundation (Clinician Scientist Fellowship to MET), the NIHR Cambridge Biomedical Research Centre (to BW, MET) and the NIHR Clinical Research Network Greenshoots award (to EGK). CJRI was supported by Deutsche Forschungsgemeinschaft (DFG) Grant SFB 1310. We acknowledge MRC funding (ref: MC_UU_00002/11).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted as part of surveillance for COVID-19 infections under the auspices of Section 251 of the NHS Act 2006. It therefore did not require individual patient consent or ethical approval. The COG-UK study protocol was approved by the Public Health England Research Ethics Governance Group (reference: R&D NR0195).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data analysed were generated by previous research studies and are available from the GISAID server. A list of sequence IDs are provided in Supplementary Material. Sequences and accompanying metadata has been uploaded onto the MRC-CLIMB server. https://www.gisaid.org https://www.climb.ac.uk/ ER -